ACS Medicinal Chemistry Letters
Page 6 of 11
REFERENCES
1
(16) Fadda, A. A.; El-Mekabaty, A.; Elattar, K. M., Chemistry of Enami-
nonitriles of Pyrano[2,3-c]pyrazole and Related Compounds. Synth. Com-
mun. 2013, 43, (20), 2685-2719.
2
3
4
5
6
7
8
9
(1) Dunn, G. P.; Old, L. J.; Schreiber, R. D., The immunobiology of can-
cer immunosurveillance and immunoediting. Immunity 2004, 21, (2), 137-
148.
(2) Kershaw, M. H.; Westwood, J. A.; Slaney, C. Y.; Darcy, P. K., Clinical
application of genetically modified T cells in cancer therapy. Clin. Transl. Im-
munology 2014, 3, (5), e16.
(3) Zou, W., Immunosuppressive networks in the tumour environment
and their therapeutic relevance. Nat. Rev. Cancer 2005, 5, (4), 263-274.
(4) Munn, D. H.; Mellor, A. L., Indoleamine 2,3-dioxygenase and tumor-
induced tolerance. J. Clin. Invest. 2007, 117, (5), 1147-1154.
(17) Rohrig, U. F.; Majjigapu, S. R.; Grosdidier, A.; Bron, S.; Stroobant,
V.; Pilotte, L.; Colau, D.; Vogel, P.; Van den Eynde, B. J.; Zoete, V.; Mich-
ielin, O., Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxy-
genase 1 inhibition. J. Med. Chem. 2012, 55, (11), 5270-5290.
(18) Rohrig, U. F.; Awad, L.; Grosdidier, A.; Larrieu, P.; Stroobant, V.;
Colau, D.; Cerundolo, V.; Simpson, A. J. G.; Vogel, P.; Van den Eynde, B. J.;
Zoete, V.; Michielin, O., Rational Design of Indoleamine 2,3-Dioxygenase
Inhibitors. J. Med. Chem. 2010, 53, (3), 1172-1189.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(5) Okamoto, A.; Nikaido, T.; Ochiai, K.; Takakura, S.; Saito, M.; Aoki,
Y.; Ishii, N.; Yanaihara, N.; Yamada, K.; Takikawa, O.; Kawaguchi, R.; Ison-
ishi, S.; Tanaka, T.; Urashima, M., Indoleamine 2,3-dioxygenase serves as a
marker of poor prognosis in gene expression profiles of serous ovarian cancer
cells. Clin. Cancer Res. 2005, 11, (16), 6030-6039.
(6) Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Par-
mentier, N.; Boon, T.; Van den Eynde, B. J., Evidence for a tumoral immune
resistance mechanism based on tryptophan degradation by indoleamine 2,3-
dioxygenase. Nat. Med. 2003, 9, (10), 1269-74.
(19) Matsuno, K.; Takai, K.; Isaka, Y.; Unno, Y.; Sato, M.; Takikawa, O.;
Asai, A., S-benzylisothiourea derivatives as small-molecule inhibitors of in-
doleamine-2,3-dioxygenase. Bioorg. Med. Chem. Lett. 2010, 20, (17), 5126-
5129.
(20) Travers, M. T.; Gow, I. F.; Barber, M. C.; Thomson, J.; Shennan, D.
B., Indoleamine 2,3-dioxygenase activity and L-tryptophan transport in hu-
man breast cancer cells. Biochim. Biophys. Acta Biomem. 2004, 1661, (1),
106-112.
(21) Yang, S. S.; Li, X. S.; Hu, F. F.; Li, Y. L.; Yang, Y. Y.; Yan, J. K.; Kuang,
C. X.; Yang, Q., Discovery of Tryptanthrin Derivatives as Potent Inhibitors
of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung
Cancer (LLC) Tumor-Bearing Mice. J. Med. Chem. 2013, 56, (21), 8321-
8331.
(22) Kumar, S.; Jaller, D.; Patel, B.; LaLonde, J. M.; DuHadaway, J. B.;
Malachowski, W. P.; Prendergast, G. C.; Muller, A. J., Structure based devel-
opment of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygen-
ase. J. Med. Chem. 2008, 51, (16), 4968-4977.
(7) Wichers, M. C.; Maes, M., The role of indoleamine 2,3-dioxygenase
(IDO) in the pathophysiology of interferon-alpha-induced depression. J.
Psychiatry. Neurosci. 2004, 29, (1), 11-17.
(8) Paul, S.; Roy, A.; Deka, S. J.; Panda, S.; Trivedi, V.; Manna, D., Nitro-
benzofurazan derivatives of N'-hydroxyamidines as potent inhibitors of in-
doleamine-2,3-dioxygenase 1. Eur. J. Med. Chem. 2016, 121, 364-375.
(9) Hou, D. Y.; Muller, A. J.; Sharma, M. D.; DuHadaway, J.; Banerjee,
T.; Johnson, M.; Mellor, A. L.; Prendergast, G. C.; Munn, D. H., Inhibition
of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-me-
thyl-tryptophan correlates with antitumor responses. Cancer Res. 2007, 67,
(2), 792-801.
(10) Muller, A. J.; DuHadaway, J. B.; Donover, P. S.; Sutanto-Ward, E.;
Prendergast, G. C., Inhibition of indoleamine 2,3-dioxygenase, an immuno-
regulatory target of the cancer suppression gene Bin1, potentiates cancer
chemotherapy. Nat. Med. 2005, 11, (3), 312-319.
(23) Tojo, S.; Kohno, T.; Tanaka, T.; Kamioka, S.; Ota, Y.; Ishii, T.; Ka-
mimoto, K.; Asano, S.; Isobe, Y., Crystal Structures and Structure-Activity
Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors. ACS Med.
Chem. Lett. 2014, 5, (10), 1119-1123.
(11) Rohrig, U. F.; Majjigapu, S. R.; Vogel, P.; Zoete, V.; Michielin, O.,
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) In-
hibitors. J. Med. Chem. 2015, 11, 312-319.
(12) Yu, L. F.; Li, Y. Y.; Su, M. B.; Zhang, M.; Zhang, W.; Zhang, L. N.;
Pang, T.; Zhang, R. T.; Liu, B.; Li, J. Y.; Li, J.; Nan, F. J., Development of
Novel Alkene Oxindole Derivatives As Orally Efficacious AMP-Activated
Protein Kinase Activators. ACS Med. Chem. Lett. 2013, 4, (5), 475-480.
(13) Yue, E. W.; Douty, B.; Wayland, B.; Bower, M.; Liu, X.; Leffet, L.;
Wang, Q.; Bowman, K. J.; Hansbury, M. J.; Liu, C.; Wei, M.; Li, Y.; Wynn,
R.; Burn, T. C.; Koblish, H. K.; Fridman, J. S.; Metcalf, B.; Scherle, P. A.;
Combs, A. P., Discovery of potent competitive inhibitors of indoleamine 2,3-
dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse
melanoma model. J. Med. Chem. 2009, 52, (23), 7364-7367.
(14) Malachowski, W. P.; Winters, M.; DuHadaway, J. B.; Lewis-Balles-
ter, A.; Badir, S.; Wai, J.; Rahman, M.; Sheikh, E.; LaLonde, J. M.; Yeh, S. R.;
Prendergast, G. C.; Muller, A. J., O-alkylhydroxylamines as rationally-de-
signed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. Eur.
J. Med. Chem. 2016, 108, 564-576.
(15) Huang, Q.; Zheng, M. F.; Yang, S. S.; Kuang, C. X.; Yu, C. J.; Yang,
Q., Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-
1,2, 3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors. Eur. J.
Med. Chem. 2011, 46, (11), 5680-5687.
ACS Paragon Plus Environment